Gene therapy for HIV/AIDS: The potential for a new therapeutic regimen

Journal of Gene Medicine

Volumn 5, Issue 8, 2003, Pages 645-653

  Fanning, Greg ^a   Amado, Rafael ^b   Gymonds, Geoff ^a  

^a Johnson and Johnson Research   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene therapy; Hematopoietic cells; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CD4 ANTIGEN; CELL ANTIBODY; CHEMOKINE RECEPTOR CCR5; DOUBLE STRANDED RNA; GAG PROTEIN; GANCICLOVIR; HAMMERHEAD RIBOZYME; LENTIVIRUS VECTOR; PROTEINASE INHIBITOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR; REV PROTEIN; RIBOZYME; RNA DIRECTED DNA POLYMERASE INHIBITOR; THYMIDINE KINASE; ZIDOVUDINE; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIVIRAL ACTIVITY; CELL BASED GENE THERAPY; CELL PROTECTION; CELLULAR IMMUNITY; CLINICAL TRIAL; DNA MODIFICATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE TRANSFER; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEM CELL MOBILIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INHIBITION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS VIRULENCE; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIGENS, CD4; GENE PRODUCTS, REV; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOPOIETIC STEM CELLS; HIV-1; HUMANS; RNA, CATALYTIC; RNA, VIRAL; T-LYMPHOCYTES;

EID: 3042615391     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.436     Document Type: Review

References (67)

1. Baltimore D. Gene therapy. Intracellular immunization. Nature 1988; 335: 395-396.
2. Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 1989; 59: 113-120.
3. Malim MH, Bohnlein HS, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator-derivation of a transdominant repressor of Rev function. Cell 1989; 58: 205-214.
4. Rhodes A, James W. Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA. J Gen Virol 1990; 71: 1965-1974.
5. Sczakiel G, Pawlita M, Kleinheinz A. Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5′-leader/gag region. Biochem Biophys Res Commun 1990; 169: 643-651.
6. Sarver N, Cantin EM, Chang PS, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 1990; 247: 1222-1225.
7. Sun LQ, Wang L, Gerlach WL, Symonds G. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucleic Acids Res 1995; 23: 2909-2913.
8. Ojwang JO, Hampel A, Looney DJ, Wong-Staal F, Rappaport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci U S A 1992; 89: 10 802-10 806.
9. Bevec D, Dobrovnik M, Hauber J, Bohnlein E. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci U S A 1992; 89: 9870-9874.
10. Duan L, Zhang H, Oakes JW, Bagasra O, Pomerantz RJ. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. Hum Gene Ther 1994; 5: 1315-1324.
11. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990; 63: 601-608.
12. Lee TC, Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 1992; 4: 66-74.
13. Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8 681-686.
14. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438.
15. Joshi P, Prasad VR. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J Virol 2002; 76: 6545-6557.
16. Wang L, Witherington C, King A, et al. Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum Gene Ther 1998; 9: 1283-1291.
17. Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med 1989; 111: 973-981.
18. Lane HC, Zunich KM, Wilson W, et al. Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. Ann Intern Med 1990; 113: 512-519.
19. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53: 557-593.
20. Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood 2001; 98 3857-3859.
21. Molina A, Krishnan AY, Nademanee A, et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000; 89: 680-689.
22. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
23. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
24. Lupton SD, Brunton LL, Kalberg VA, Overell RW. Dominant positive and negative selection using a hygromycin phosphotransferase-thymidine kinase fusion gene. Mol Cell Biol 1991; 11: 3374-3378.
25. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-223.
26. Walker R, Blaese RM, Carter CS, et al. A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins. Hum Gene Ther 1993; 4: 659-680.
27. Walker RE, Carter CS, Muul L, et al. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med 1998; 4: 852-856.
28. Galpin JE, Casciato DA, Richards SB. A phase I clinical trial to evaluate the safety and biological activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatic HIV-1 infected subjects. Hum Gene Ther 1994; 5: 997-1017.
29. Ziegner UH, Peters G, Jolly DJ, et al. Cytotoxic T-lymphocyte induction in asymptomatic HIV-1-infected patients immunized with Retrovector-transduced autologous fibroblasts expressing HIV-1IIIB Env/Rev proteins. Aids 1995; 9: 43-50.
30. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 1996; 93: 2889-2894.
31. Nabel GJ, Fox BA, Post L, Thompson CB, Woffendin C. A molecular genetic intervention for AIDS - effects of a transdominant negative form of Rev. Hum Gene Ther 1994; 5: 79-92.
32. Ranga U, Woffendin C, Verma S, et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A 1998; 95: 1201-1206.
33. Morgan RA, Walker R. Gene therapy for AIDS using retroviral mediated gene transfer to deliver HIV-1 antisense TAR and transdominant Rev protein genes to syngeneic lymphocytes in HIV-1 infected identical twins. Hum Gene Ther 1996; 7: 1281-1306.
34. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998; 9: 2407-2425.
35. Buchschacher GL Jr, Wong-Staal F. Approaches to gene therapy for human immunodeficiency virus infection. Hum Gene Ther 2001; 12: 1013-1019.
36. Cooper D, Penny R, Symonds G, et al. A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins. Hum Gene Ther 1999; 10: 1401-1421.
37. Knop AE, Arndt AJ, Raponi M, Boyd MP, Ely JA, Symonds G. Artificial capillary culture: expansion and retroviral transduction of CD4+ T-lymphocytes for clinical application. Gene Ther 1999; 6 373-384.
38. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-793.
39. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000; 96: 467-474.
40. Deeks SG, Wagner B, Anton PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther 2002; 5: 788-797.
41. Neal TF, Holland HK, Baum CM, et al. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995; 86: 1749-1756.
42. von Laer D, Hufert FT, Fenner TE, et al. CD34+ hematopoietic progenitor cells are not a major reservoir of the human immunodeficiency virus. Blood 1990; 76: 1281-1286.
43. Slobod KS, Bennett TA, Freiden PJ, et al. Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996; 88: 3329-3335.
44. Campbell TB, Sevin A, Coombs RW, et al. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood 2000; 95: 48-55.
45. Pollok KE, Williams DA. Facilitation of retrovirus-mediated gene transfer into hematopoietic stem and progenitor cells and peripheral blood T-lymphocytes utilizing recombinant fibronectin fragments. Curr Opin Mol Ther 1999; 1: 595-604.
46. Heim DA, Hanazono Y, Giri N, et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther 2000; 1: 533-544.
47. Grossman Z, Paul WE. The impact of HIV on naive T-cell homeostasis. Nat Med 2000; 6: 976-977.
48. Hazenberg MD, Otto SA, Cohen Stuart JW, et al. Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000; 6: 1036-1042.
49. Hazenberg MD, Stuart JW, Otto SA, et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95: 249-255.
50. Mohri H, Perelson AS, Tung K, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001; 194: 1277-1287.
51. Zhang L, Lewin SR, Markowitz M, et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med 1999; 190: 725-732.
52. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690-695.
53. Douek DC, Betts MR, Hill BJ, et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 2001; 167: 6663-6668.
54. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 277: 112-116.
55. Franco JM, Rubio A, Martinez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99: 3702-3706.
56. Kohn DB, Bauer G, Rice CR, et al. A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children. Blood 1999; 94: 368-371.
57. Bahner I, Kearns K, Hao QL, Smogorzewska EM, Kohn DB. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J Virol 1996; 70: 4352-4360.
58. Haynes BF, Markert ML, Sempowski GD, Patel DD, Hale LP. The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. Annu Rev Immunol 2000; 18 529-560.
59. Juttner CA, Fibbe WE, Nemunaitis J, Kanz L, Gianni AM. Blood cell transplantation: report from an International Consensus Meeting. Bone Marrow Transplant 1994; 14: 689-693.
60. Kang EM, de Witte M, Malech H, et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 2002; 99: 698-701.
61. Amado RG, Mitsuyasu RT, Symonds G, et al. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme. Hum Gene Ther 1999; 10: 2255-2270.
62. Amado RG, Mitsuyasu RT, Ngok FK, et al. Multilineage engraftment and preferential survival of ribozyme containing CD4+ T-lymphocytes derived from CD34+ progenitor cells in a phase I study in HIV-1. Mol Ther 2002; 5: S290.
63. Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol 2002; 13: 429-436.
64. Mautino MR. Lentiviral vectors for gene therapy of HIV-1 infection. Curr Gene Ther 2002; 2: 23-43.
65. Arteaga HJ, Hinkula J, Van Dijk-Hard I, et al. Choosing CCR5 or Rev siRNA in HIV-1. Nat Biotechnol 2003; 21: 230-231.
66. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
67. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-256.